MedTrace Logo

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

NCT00084695 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-01-10

No results posted yet for this study

Summary

RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.

PURPOSE: This phase II trial is studying how well umbilical cord blood works as a source of stem cells in treating patients with types of cancer as well as other diseases.

Conditions

Interventions

BIOLOGICAL

anti-thymocyte globulin

Given IV

DRUG

busulfan

Given orally

DRUG

cyclophosphamide

Given IV

DRUG

fludarabine phosphate

Given IV

DRUG

melphalan

Given IV

DRUG

methylprednisolone

Given IV

RADIATION

radiation therapy

Patients undergo radiation therapy two times daily on days -7 to -4.

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Kenneth G. Lucas, MD · Milton S. Hershey Medical Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00084695 on ClinicalTrials.gov